Claims for Patent: 11,097,063
✉ Email this page to a colleague
Summary for Patent: 11,097,063
| Title: | Syringe device with a dose limiting mechanism and an additional safety mechanism |
| Abstract: | A syringe device for ejecting a dose of a medicament, the syringe device comprising: a dose limiting mechanism arranged to interact with a dose ejecting mechanism to prevent ejection of a dose exceeding a set dose, and a safety mechanism, which is arranged such with respect to the dose ejecting mechanism that, if the dose limiting mechanism fails, the safety mechanism prevents ejection of a dose exceeding the set dose. |
| Inventor(s): | Eiland Jacob, Enggaard Christian Peter, Moeller Claus Schmidt, Markussen Tom Hede |
| Assignee: | Novo Nordisk A/S |
| Application Number: | US16250620 |
| Patent Claims: |
Details for Patent 11,097,063
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc. | LEVEMIR | insulin detemir | Injection | 021536 | June 16, 2005 | ⤷ Subscribe | 2039-01-17 |
| Novo Nordisk Inc. | LEVEMIR | insulin detemir | Injection | 021536 | October 31, 2013 | ⤷ Subscribe | 2039-01-17 |
| Novo Nordisk Inc. | TRESIBA | insulin degludec | Injection | 203314 | September 25, 2015 | ⤷ Subscribe | 2039-01-17 |
| Novo Nordisk Inc. | TRESIBA | insulin degludec | Injection | 203314 | November 21, 2018 | ⤷ Subscribe | 2039-01-17 |
| Novo Nordisk Inc. | FIASP | insulin aspart | Injection | 208751 | September 29, 2017 | ⤷ Subscribe | 2039-01-17 |
| Novo Nordisk Inc. | FIASP | insulin aspart | Injection | 208751 | September 24, 2018 | ⤷ Subscribe | 2039-01-17 |
| Novo Nordisk Inc. | FIASP | insulin aspart | Injection | 208751 | June 21, 2023 | ⤷ Subscribe | 2039-01-17 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
